Membrane Fas ligand activates innate immunity and terminates ocular immune privilege

被引:63
作者
Gregory, MS
Repp, AC
Holhbaum, AM
Saff, RR
Marshak-Rothstein, A
Ksander, BR
机构
[1] Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA
[2] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA
关键词
D O I
10.4049/jimmunol.169.5.2727
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It has been proposed that the constitutive expression of Fas ligand (FasL) in the eye maintains immune privilege, in part through inducing apoptosis of infiltrating Fas(+) T cells. However, the role of FasL in immune privilege remains controversial due to studies that indicate FasL is both pro- and anti-inflammatory. To elucidate the mechanism(s) by which FasL regulates immune privilege, we used an ocular tumor model and examined the individual roles of the membrane-bound and soluble form of FasL in regulating ocular inflammation. Following injection into the privileged eye, tumors expressing only soluble FasL failed to trigger inflammation and grew progressively. By contrast, tumors expressing only membrane FasL 1) initiated vigorous neutrophil-mediated inflammation, 2) terminated immune privilege, and 3) were completely rejected. Moreover, the rejection coincided with activation of both innate and adaptive immunity. Interestingly, a higher threshold level of membrane FasL on tumors is required to initiate inflammation within the immune privileged eye, as compared with nonprivileged sites., The higher threshold is due to the suppressive microenvironment found within aqueous humor that blocks membrane FasL activation of neutrophils. However, aqueous humor is unable to completely block the proinflammatory effects of tumor cells that express high levels of membrane FasL. In conclusion, our data indicate that the function of FasL on intraocular tumors is determined by the microenvironment in conjunction with the form and level of FasL expressed.
引用
收藏
页码:2727 / 2735
页数:9
相关论文
共 37 条
[11]   Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction [J].
Kang, SM ;
Schneider, DB ;
Lin, ZH ;
Hanahan, D ;
Dichek, DA ;
Stock, PG ;
Baekkeskov, S .
NATURE MEDICINE, 1997, 3 (07) :738-743
[12]   METALLOPROTEINASE-MEDIATED RELEASE OF HUMAN FAS LIGAND [J].
KAYAGAKI, N ;
KAWASAKI, A ;
EBATA, T ;
OHMOTO, H ;
IKEDA, S ;
INOUE, S ;
YOSHINO, K ;
OKUMURA, K ;
YAGITA, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) :1777-1783
[13]   Macrophage inflammatory protein-2 is a mediator of polymorphonuclear neutrophil influx in ocular bacterial infection [J].
Kernacki, KA ;
Barrett, RP ;
Hobden, JA ;
Hazlett, LD .
JOURNAL OF IMMUNOLOGY, 2000, 164 (02) :1037-1045
[14]   Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice [J].
Lau, HT ;
Yu, M ;
Fontana, A ;
Stoeckert, CJ .
SCIENCE, 1996, 273 (5271) :109-112
[15]  
LAWRENCE DA, 1991, METHOD ENZYMOL, V198, P327
[16]  
LUCKENBACH MW, 1985, INVEST OPHTH VIS SCI, V26, P1368
[17]   PROTEOLYTIC ACTIVATION OF LATENT TRANSFORMING GROWTH FACTOR-BETA FROM FIBROBLAST-CONDITIONED MEDIUM [J].
LYONS, RM ;
KESKIOJA, J ;
MOSES, HL .
JOURNAL OF CELL BIOLOGY, 1988, 106 (05) :1659-1665
[18]  
MEDEWAR PB, 1945, J ANAT, V79, P157
[19]  
MEDEWAR PB, 1948, BR J EXP PATHOL, V29, P58
[20]   THE FAS DEATH FACTOR [J].
NAGATA, S ;
GOLSTEIN, P .
SCIENCE, 1995, 267 (5203) :1449-1456